COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

https://panaceapharma.com/

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Feb 1, 2018

Panacea Pharmaceuticals Completes Enrollment in Phase 1 Study of First-in-Class Cancer Vaccine Therapy in Patients with Persistent Prostate Cancer

Mar 30, 2017

Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes

Mar 30, 2017

Panacea Pharmaceuticals, Inc. Presents Data on Targeted Killing of Leukemia Cells By Its Radiolabeled Monoclonal Antibody to the Cancer Biomarker HAAH

Jan 17, 2017

Panacea Pharmaceuticals Initiates Phase I Study of First-in-Class Cancer Vaccine Therapy Candidate in Patients with Persistent Prostate Cancer

Dec 8, 2015

Panacea Pharmaceuticals closes its Series E financing for a total of $15 million to fund the Phase 1 clinical study of its lead cancer immunotherapeutic drug and pursue its late stage pre-clinical candidates toward integrated cancer management

For More Press Releases

---